Engineered Immune Effectors Against Cervical Cancer

Sponsor
Shenzhen Geno-Immune Medical Institute
Study ID
NCT03362619
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
10 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • CC-EIEs — BIOLOGICAL
    2 to 4 infusions, once a week, for 1x10\^5\~1x10\^7 CTLs/kg via IV, abdominal cavity or intratumoral injection each time

Study Details

The primary objective of this study is to evaluate the safety of cervical cancer specific engineered immune effectors (CC-EIEs). The secondary objectives are to evaluate the rate of successful CC-EIE generation in vitro and determine the anti-CC efficacy.

Key Dates

Start date
Jun 1, 2026
Status verified
May 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2030

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CC-EIEs
    Autologous cervical cancer specific engineered immune effectors (EIEs)

Primary Outcome Measure

Safety of CC-EIEs in patients using CTCAE version 4.0 standard to evaluate the level of adverse events [ Time Frame: 6 months ]

Central Contacts

Related Studies